Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valaciclovir for EBV Suppression in COPD
NCT03699904Phase 2Terminated
- Sponsor
- Belfast Health and Social Care Trust
- Start
- Oct 2018
- Primary completion
- May 2020
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of valaciclovir in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Belfast Health and Social Care Trust. Primary endpoints: Incidence of Serious Adverse Reactions (SARs) and EBV viral load at 8 weeks. Started Oct 2018; status: terminated.
02
Drugs
valaciclovir
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03699904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03699904.